Camidge R, et al. Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: first report of a phase 3 trial (ALTA-1L). IASLC 2018, abstract PL02.03.
Commissie voor Beentumoren nog steeds onmisbaar
apr 2022 | Bot en wekedelentumoren, Orthopedie